Compare AORT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | MNKD |
|---|---|---|
| Founded | 1984 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1996 | 2004 |
| Metric | AORT | MNKD |
|---|---|---|
| Price | $26.88 | $3.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $49.40 | $8.69 |
| AVG Volume (30 Days) | 719.0K | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $298,836,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $14.20 | $35.81 |
| Revenue Next Year | $11.20 | $11.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.01 | ★ 22.23 |
| 52 Week Low | $19.16 | $2.23 |
| 52 Week High | $48.25 | $6.51 |
| Indicator | AORT | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 48.70 |
| Support Level | $25.79 | $3.74 |
| Resistance Level | $28.29 | $4.23 |
| Average True Range (ATR) | 1.15 | 0.17 |
| MACD | -0.31 | -0.00 |
| Stochastic Oscillator | 20.02 | 45.30 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.